Lead Sponsor

St. Petersburg State Pavlov Medical University

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Patients must have an indication for allogeneic hematopoietic stem cell transplantation with myeloablative conditioning for malignant disease
•Patients with 5-9/10 HLA-matched related donor available. The donor and recipient must be identical by the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1.
•Peripheral blood stem cells or bone marrow as a graft source
•No second malignancies requiring treatment
•No severe concurrent illness

•Titer of anti-HLA antibodies ≥ 5000 at the time of inclusion
•Moderate or severe cardiac dysfunction, left ventricular ejection fraction \<50%
•Moderate or severe decrease in pulmonary function, FEV1 \<70% or DLCO\<70% of predicted
•Respiratory distress \>grade I
•Severe organ dysfunction: AST or ALT \>5 upper normal limits, bilirubin \>1.5 upper normal limits, creatinine \>2 upper normal limits
•Creatinine clearance \< 60 mL/min
•Uncontrolled bacterial or fungal infection at the time of enrollment
•Requirement for vasopressor support at the time of enrollment
•Karnofsky index \<30%
•Pregnancy
•Somatic or psychiatric disorder making the patient unable to sign informed consent

Related studies

NCT04307576 · Leukemia, Acute Lymphoblastic

NCT06855810 · Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, and more

NCT05794880 · Leukemia, Acute Myeloid Leukemia in Remission, and more

NCT06756152 · Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, and more

NCT06101381 · Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)